Interaction of GLP-1 agonists with Exercise and Nutrition on Muscle Health and Glucose Regulation

Interaction of GLP-1 agonists with Exercise and Nutrition on Muscle Health and Glucose Regulation | Recording

Member Exclusive Recorded Webinar

GLP-1 agonists are increasingly used to promote weight loss and improve blood glucose control. Some health professionals are concerned about muscle mass loss. This webinar discusses the potential interaction of these pharmaceutical agents with exercise and nutrition in an effort to promote evidence-based decisions about patient care.

Overview

GLP-1 agonists are increasingly used to promote weight loss and improve blood glucose control. Some health professionals are concerned about muscle mass loss. This webinar discusses the potential interaction of these pharmaceutical agents with exercise and nutrition in an effort to promote evidence-based decisions about patient care.

Learning Objectives

Role of nutrition on muscle mass and general health during GLP-1 agonist use.
Impact of resistance exercise on muscle mass during GLP-1 agonist use.
Interaction of aerobic exercise and GLP-1 agonists on glucose regulation independent of muscle mass.

Speakers

	Laura Russel, MA, RDN CDCES, Endocrinology Clinic of Minneapolis Laura Russel has 20 years of experience as a Registered Dietitian Nutritionist and 15 years as a Diabetes Care & Education Specialist. Her most recent positions include private practice through Fay Nutrition and Diabetes Educator and Program Coordinator at Endocrinology Clinic of Minneapolis in Minnesota. She has worked in various settings including research, inpatient care, telemedicine and outpatient clinics. Her expertise includes medication management and technology related to diabetes care. She has presented at the Food & Nutrition Conference and Expo® on continuous glucose monitoring (2016 & 2024), weight management for type 2 diabetes (2023), and the role of the RDN in preventing clinical inertia (2022). She has volunteered with Diabetes Dietetic Practice Group for 12 years in various roles including Chair in 2023-2024. She serves on the Technology & Favorably Reviewed committees with the Association of Diabetes Care & Education Specialists (ADCES) and is the current Foundation Chair with the Minnesota Academy of Nutrition & Dietetics.
	Danny Green, PhD, University of Western Austrailia Danny is a Winthrop Professor based in the School of Human Sciences (Sport and Exercise Science). A recent NHMRC Principal Research Fellow, he is a cardiovascular exercise physiologist specializing in the prevention of chronic disease. His research encompasses the lifespan; from exercise training in the prevention of the development of atherosclerosis in obese children and adolescents, to research on the best combination of exercise and medications in the management of patients with coronary disease, stroke, hypercholesterolaemia, diabetes and heart failure patients awaiting transplantation.
	Flemming Dela, MD, University of Copenhagen Flemming Dela is a professor at the University of Copenhagen, Denmark, with extensive expertise in human physiology, metabolism, and endocrinology. His research focuses on insulin action, glucose metabolism, and the physiological effects of exercise, particularly in individuals with type 2 diabetes. In this webinar, Professor Dela will discuss "Pancreatic Beta-Cell Function" in the context of GLP-1 agonists and lifestyle modifications. His talk is based on findings from his recent study, "Effects of aerobic training and semaglutide treatment on pancreatic beta-cell secretory function in patients with type 2 diabetes" (PubMed: 37265222), which explores the combined impact of exercise and semaglutide on beta-cell function in type 2 diabetes management.

Moderators

Steven K. Malin, PhD, FACSM, Robert Wood Johnson Medical School

Janice MacLeod, MA, RD, CDCES, FADCES

Summary

Availability:

On-Demand

Cost:

FREE

Credit Offered:

No Credit Offered

Create Account